Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.

Journal of lipid mediators Pub Date : 1993-08-01
J M Herbert, L Fraisse, A Bachy, G Valette, P Savi, M C Laplace, J Lassalle, B Roche, A Lale, P E Keane
{"title":"Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist.","authors":"J M Herbert,&nbsp;L Fraisse,&nbsp;A Bachy,&nbsp;G Valette,&nbsp;P Savi,&nbsp;M C Laplace,&nbsp;J Lassalle,&nbsp;B Roche,&nbsp;A Lale,&nbsp;P E Keane","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>SR 27388 (N-(2-dimethylaminoethyl)-N-(3-pyridinylmethyl[4-(3,5-di(tert- butyl)-4-hydroxylphenyl)thiazol-2-yl]amine) is a potent and competitive antagonist of the binding of [3H]PAF to its receptor on rabbit platelets exhibiting an equilibrium inhibition constant for PAF binding of 10.5 +/- 1.2 nM (n = 3). SR 27388 potently inhibited PAF-induced aggregation of rabbit platelets in vitro (IC50 = 65 +/- 12 nM) (n = 4). In this respect, SR 27388 was as potent as the triazolothienodiazepine WEB-2086 against PAF-induced aggregation of rabbit platelets and had no effect on the action of other platelet aggregating agents. SR 27388 prevented in a dose-dependent manner the formation of thiobarbituric acid reactive substances during membrane peroxidation (IC50 = 0.7 microM) and inhibited reduction of the stable 1,1-diphenyl-2-picrylhydrazyl radical, indicating that the antioxidant potency of SR 27388 was due to an efficient radical scavenging activity. SR 27388 displayed marked in vitro inhibition of zymosan-induced oxidative burst in human monuclear cells (IC50 = 3 microM). In vivo, SR 27388 protected mice from 100 micrograms/kg PAF-induced death with an ED50 value of 500 micrograms/kg, when given i.v., 5 min before PAF challenge or p.o. (ED50 = 800 micrograms/kg) when given 1 h before PAF administration. Similarly, i.v. or oral doses of SR 27388 afforded in mice complete protection against endotoxin-induced lethality (ED50 values were 250 micrograms/kg and 1.3 mg/kg, respectively). Neither BHT, vitamin E nor catechin exhibited significant protection against PAF- or endotoxin-induced death. In ovalbumin-presensitized rabbits, SR 27388 premixed with the allergen inhibited in a dose-dependent manner allergen-induced oedema formation in the skin (ED50 = 0.1 mumol/site). After an i.v. administration of 10 mg/kg, SR 27388 significantly protected mice against alloxan-induced diabetes. These results show that SR 27388 is a potent and orally active dual PAF receptor antagonist and antioxidant.</p>","PeriodicalId":16323,"journal":{"name":"Journal of lipid mediators","volume":"8 1","pages":"31-51"},"PeriodicalIF":0.0000,"publicationDate":"1993-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of lipid mediators","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

SR 27388 (N-(2-dimethylaminoethyl)-N-(3-pyridinylmethyl[4-(3,5-di(tert- butyl)-4-hydroxylphenyl)thiazol-2-yl]amine) is a potent and competitive antagonist of the binding of [3H]PAF to its receptor on rabbit platelets exhibiting an equilibrium inhibition constant for PAF binding of 10.5 +/- 1.2 nM (n = 3). SR 27388 potently inhibited PAF-induced aggregation of rabbit platelets in vitro (IC50 = 65 +/- 12 nM) (n = 4). In this respect, SR 27388 was as potent as the triazolothienodiazepine WEB-2086 against PAF-induced aggregation of rabbit platelets and had no effect on the action of other platelet aggregating agents. SR 27388 prevented in a dose-dependent manner the formation of thiobarbituric acid reactive substances during membrane peroxidation (IC50 = 0.7 microM) and inhibited reduction of the stable 1,1-diphenyl-2-picrylhydrazyl radical, indicating that the antioxidant potency of SR 27388 was due to an efficient radical scavenging activity. SR 27388 displayed marked in vitro inhibition of zymosan-induced oxidative burst in human monuclear cells (IC50 = 3 microM). In vivo, SR 27388 protected mice from 100 micrograms/kg PAF-induced death with an ED50 value of 500 micrograms/kg, when given i.v., 5 min before PAF challenge or p.o. (ED50 = 800 micrograms/kg) when given 1 h before PAF administration. Similarly, i.v. or oral doses of SR 27388 afforded in mice complete protection against endotoxin-induced lethality (ED50 values were 250 micrograms/kg and 1.3 mg/kg, respectively). Neither BHT, vitamin E nor catechin exhibited significant protection against PAF- or endotoxin-induced death. In ovalbumin-presensitized rabbits, SR 27388 premixed with the allergen inhibited in a dose-dependent manner allergen-induced oedema formation in the skin (ED50 = 0.1 mumol/site). After an i.v. administration of 10 mg/kg, SR 27388 significantly protected mice against alloxan-induced diabetes. These results show that SR 27388 is a potent and orally active dual PAF receptor antagonist and antioxidant.

双抗氧化剂和PAF受体拮抗剂SR 27388的生化和药理学性质
SR 27388 (N-(2-二甲氨基乙基)-N-(3-吡啶基甲基[4-(3,5-二(叔丁基)-4-羟基苯基)噻唑-2-基]胺)是一种有效的、竞争性的抗[3H]PAF在兔血小板上与其受体结合的拮抗剂,对PAF结合的平衡抑制常数为10.5 +/- 1.2 nM (N = 3)。SR 27388在体外有效抑制PAF诱导的兔血小板聚集(IC50 = 65 +/- 12 nM) (N = 4)。SR 27388对paf诱导的兔血小板聚集的抑制作用与三唑噻吩二氮平WEB-2086相同,对其他血小板聚集剂的作用无影响。sr27388在膜过氧化过程中以剂量依赖的方式阻止硫代巴比妥酸反应物质的形成(IC50 = 0.7微米),并抑制稳定的1,1-二苯基-2-picrylhydrazyl自由基的还原,表明sr27388的抗氧化能力是由于其有效的自由基清除活性。sr27388对酵素诱导的人单核细胞氧化破裂有明显的体外抑制作用(IC50 = 3微米)。在体内,sr27388可保护小鼠免于100微克/公斤PAF诱导的死亡,在PAF攻击前5分钟静脉注射时ED50值为500微克/公斤,在PAF给药前1小时静脉注射时ED50值为800微克/公斤。同样,静脉或口服剂量的sr27388对小鼠提供完全保护,使其免受内毒素引起的死亡(ED50值分别为250微克/千克和1.3毫克/千克)。BHT、维生素E和儿茶素对PAF或内毒素诱导的死亡都没有显著的保护作用。在卵清蛋白致敏的家兔中,SR 27388与过敏原预混能以剂量依赖的方式抑制过敏原诱导的皮肤水肿形成(ED50 = 0.1 μ mol/位点)。经静脉注射10 mg/kg后,SR 27388对小鼠四氧嘧啶诱导的糖尿病有明显的保护作用。结果表明,sr27388是一种有效的口服双PAF受体拮抗剂和抗氧化剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信